In a 11-min video, five experts in addiction explain why KT-110 is a game changer and why it is a hope for millions of AUD patients.

 

Henri-Jean Aubin is Professor of Psychiatry and Addictology at Hôpital Pitié-Salpétrière in Paris, France. He was the Principal Investigator in KT-110 phase 2 trial.

Karl Mann is Professor Emeritus at Central Institute of Mental Health, University of Heidelberg, Germany.

Wim van den Brink is Professor Emeritus of Psychiatry and Addiction at Academic Medical Center, University of Amsterdam, The Netherlands.

Antoni Gual is Head of the Addictions Unit Neurosciences Institute at University of Barcelona, Spain.

Raymond Anton is Professor Emeritus of Psychiatry and Addictions at Medical University of South Carolina, USA.